Kronos Bio: Targeting Dysregulated Transcription

Jorge DiMartino, MD, PhD, Chief Medical Officer and Executive VP of Clinical Development at Kronos Bio, discusses the company’s three investigational compounds being advanced for patients with cancer. The company’s investigational therapies target dysregulated transcription, which is a hallmark of cancer and other serious diseases. 

Jorge DiMartino M.D., Ph.D. joined Kronos Bio in 2019 as Chief Medical Officer and Executive Vice President, Clinical Development.   Prior to joining Kronos Bio, Jorge served as Vice President, Translational Development Oncology at Celgene. He joined Celgene in 2011 to lead early-stage oncology clinical programs and to direct the Translational Research Laboratories. In 2014, Jorge was appointed Head of the Epigenetics Thematic Center of Excellence (TCoE), a fully integrated unit driving drug discovery through clinical proof of concept efforts around epigenetic targets. During this time, he built a discovery team with industry leading epigenetic profiling capabilities in pursuit of chromatin modifier targets. His team has driven multiple epigenetic programs through Phase 1, delivering robust data packages to support proof of concept trial designs. In January 2019, Jorge added responsibility for Protein Homeostasis TCoE and joined the Research Management Team to governance for discovery programs from Target ID to development candidate nomination. Prior to joining Celgene, Jorge was Group Medical Director at Genentech in the Oncology Exploratory Clinical Development group.   There he led early clinical development of the hedgehog pathway inhibitor, vismodegib and was Development Team Lead for the BCL2 inhibitor programs (navitoclax and venetoclax). Jorge received his Ph.D. in Immunology from Cornell University Graduate School of Medical Sciences, and his M.D. from University of California San Diego.   He completed a residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology, both at Stanford University School of Medicine where he continues to see pediatric oncology patients as a member of the Adjunct Clinical Faculty.